Evidence map›Paper›PMID 20031443›Full record

ReviewJournal of photochemistry and photobiology. B, Biology2010

Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications.

Frederic Leblond, Scott C Davis, Pablo A Valdés, Brian W Pogue

Abstract readReview
In one paragraph

Review in Journal of photochemistry and photobiology. B, Biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Tracing theEnvironment & health (Washington, D.C.) · 2026
    Article
  4. Article
  5. Expert review of respiratory medicine · 2026
    Review
  6. Article
  7. Article
  8. Near-Infrared In Vivo Whole Body Fluorescence Imaging of Peptide Nucleic Acid.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  9. Article
  10. A programmable genetic platform for engineering noninvasive biosensors.bioRxiv : the preprint server for biology · 2025
    Article
  11. Article
  12. Review
  13. Review
  14. Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Lessons learned in application driven imaging agent design for image-guided surgery.European journal of nuclear medicine and molecular imaging · 2024
    Review
  20. Article

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Frederic LeblondThayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA. frederic.leblond@dartmouth.edu
Scott C Davis
Pablo A Valdés
Brian W Pogue

Funding

Fluorescence Imaging to Optimize Cancer TherapyR01CA109558 · NCI · DARTMOUTH COLLEGE · PI POGUE, BRIAN WILLIAM · 2005 to 2015
$2.8M
Micro CT/NIR Molecular Imaging of CancerR01CA120368 · NCI · DARTMOUTH COLLEGE · PI POGUE, BRIAN WILLIAM · 2007 to 2011
$1.2M
X-ray/Fluorescence Molecular and Diffuse Optical Tomography of GliomaK25CA138578 · NCI · DARTMOUTH COLLEGE · PI LEBLOND, FREDERIC · 2009 to 2012
$722k
NCI NIH HHS K25 CA138578NCI NIH HHS K25CA138578NCI NIH HHS R01 CA109558NCI NIH HHS R01CA109558NCI NIH HHS R01 CA120368NCI NIH HHS R01CA120368
6 · The paper itself

Abstract

Fluorescence sampling of cellular function is widely used in all aspects of biology, allowing the visualization of cellular and sub-cellular biological processes with spatial resolutions in the range from nanometers up to centimeters. Imaging of fluorescence in vivo has become the most commonly used radiological tool in all pre-clinical work. In the last decade, full-body pre-clinical imaging systems have emerged with a wide range of utilities and niche application areas. The range of fluorescent probes that can be excited in the visible to near-infrared part of the electromagnetic spectrum continues to expand, with the most value for in vivo use being beyond the 630 nm wavelength, because the absorption of light sharply decreases. Whole-body in vivo fluorescence imaging has not yet reached a state of maturity that allows its routine use in the scope of large-scale pre-clinical studies. This is in part due to an incomplete understanding of what the actual fundamental capabilities and limitations of this imaging modality are. However, progress is continuously being made in research laboratories pushing the limits of the approach to consistently improve its performance in terms of spatial resolution, sensitivity and quantification. This paper reviews this imaging technology with a particular emphasis on its potential uses and limitations, the required instrumentation, and the possible imaging geometries and applications. A detailed account of the main commercially available systems is provided as well as some perspective relating to the future of the technology development. Although the vast majority of applications of in vivo small animal imaging are based on epi-illumination planar imaging, the future success of the method relies heavily on the design of novel imaging systems based on state-of-the-art optical technology used in conjunction with high spatial resolution structural modalities such as MRI, CT or ultrasound.

Indexed as

AnimalsDrug Evaluation, PreclinicalFluorescenceMagnetic Resonance ImagingMiceTomographyWhole Body ImagingWhole-Body Irradiation

Identifiers

PMID20031443
PMCPMC3678966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.